This is a working overview of SR9009, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-27. Anything still debated is marked as such rather than presented as settled.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
== Difference between channels and carriers == A carrier is not open simultaneously to both the extracellular and intracellular environments. Either its inner gate is closed, or its outer gate is closed. That is, its inner and outer gates are never open at the same time. In contrast, a channel can be open to both environments at the same time, allowing the molecules to diffuse without interruption. Carriers have binding sites, but pores and channels do not. When a channel is opened, millions of ions can pass through the membrane per second, but only 100 to 1000 molecules typically pass through a carrier molecule in the same time. Each carrier protein is designed to recognize only one substance or one group of very similar substances. Research has correlated defects in specific carrier proteins with specific diseases.
=== More exotic types of decay === Other types of radioactive decay were found to emit previously seen particles but via different mechanisms. An example is internal conversion, which results in an initial electron emission, and then often further characteristic X-rays and Auger electrons emissions, although the internal conversion process involves neither beta nor gamma decay. A neutrino is not emitted, and none of the electron(s) and photon(s) emitted originate in the nucleus, even though the energy to emit all of them does originate there. Internal conversion decay, like isomeric transition gamma decay and neutron emission, involves the release of energy by an excited nuclide, without the transmutation of one element into another. Rare events that involve a combination of two beta-decay-type events happening simultaneously are known (see below). Any decay process that does not violate the conservation of energy or momentum laws (and perhaps other particle conservation laws) is permitted to happen, although not all have been detected. An interesting example discussed in a final section, is bound state beta decay of rhenium-187. In this process, the beta electron-decay of the parent nuclide is not accompanied by beta electron emission, because the beta particle has been captured into the K-shell of the emitting atom. An antineutrino is emitted, as in all negative beta decays. If energy circumstances are favorable, a given radionuclide may undergo many competing types of decay, with some atoms decaying by one route, and others decaying by another.
2 HO–CH2CH2–Cl + Ca(OH)2 → 2 (CH2CH2)O + CaCl2 + 2H2O The produced ethylene oxide is purified by distillation. The chlorohydrin process allows to reach 95% conversion of ethylene chlorohydrin. The yield of ethylene oxide is about 80% of the theoretical value; for 1 tonne (0.98 long tons; 1.1 short tons) of ethylene oxide, about 200 kg (440 lb) of ethylene dichloride is produced. But, the major drawbacks of this process are high chlorine consumption and effluent load. This process is now obsolete.
=== Eliminating Sequences === Eliminate the sequences that are more than r% identical. There are two ways to eliminate the sequences. It can be done either by removing sequences from the block or just by finding similar sequences and replace them by new sequences which could represent the cluster. Elimination is done to remove protein sequences that are more similar than the specified threshold.
== History == The first recorded observation of capillary action was by Leonardo da Vinci. A former student of Galileo, Niccolò Aggiunti, was said to have investigated capillary action. In 1660, capillary action was still a novelty to the Irish chemist Robert Boyle, when he reported that "some inquisitive French Men" had observed that when a capillary tube was dipped into water, the water would ascend to "some height in the Pipe". Boyle then reported an experiment in which he dipped a capillary tube into red wine and then subjected the tube to a partial vacuum. He found that the vacuum had no observable influence on the height of the liquid in the capillary, so the behavior of liquids in capillary tubes was due to some phenomenon different from that which governed mercury barometers. Others soon followed Boyle's lead. Some (e.g., Honoré Fabri, Jacob Bernoulli) thought that liquids rose in capillaries because air could not enter capillaries as easily as liquids, so the air pressure was lower inside capillaries. Others (e.g., Isaac Vossius, Giovanni Alfonso Borelli, Louis Carré, Francis Hauksbee, Josia Weitbrecht) thought that the particles of liquid were attracted to each other and to the walls of the capillary. Although experimental studies continued during the 18th century, a successful quantitative treatment of capillary action was not attained until 1805 by two investigators: Thomas Young of the United Kingdom and Pierre-Simon Laplace of France. They derived the Young–Laplace equation of capillary action.
Sources: en.wikipedia.org
Thyrotropin-releasing hormone (TRH) is a hypophysiotropic hormone produced by neurons in the hypothalamus that stimulates the release of thyroid-stimulating hormone (TSH) as well as prolactin from the anterior pituitary. TRH has been used clinically in diagnosis of hyperthyroidism, and for the treatment of spinocerebellar degeneration and disturbance of consciousness in humans. Its pharmaceutical form is called protirelin (INN) ().
It predominantly affects children between the ages of two and six years in the least developed countries around the world, primarily in sub-Saharan Africa. Noma survivors experience stigma, social isolation, and discrimination within their communities. These can be countered by education and community outreach programs.
=== Other nitrogen compounds === Chloroplasts make all of a cell's purines and pyrimidines—the nitrogenous bases found in DNA and RNA. They also convert nitrite (NO2−) into ammonia (NH3) which supplies the plant with nitrogen to make its amino acids and nucleotides.
I must tell you that I can make urea without the use of kidneys, either man or dog. Ammonium cyanate is urea. His second sentence was incorrect. Ammonium cyanate [NH4]+[OCN]− and urea CO(NH2)2 are two different chemicals with the same empirical formula CON2H4, which are in chemical equilibrium heavily favoring urea under standard conditions.
=== Onset and duration === The onset of action of psilocybin taken orally is 0.5 to 0.8 hours (30 to 50 minutes) on average, with a range of 0.1 to 1.5 hours (5 to 90 minutes). Peak psychoactive effects occur at about 1.0 to 2.2 hours (60 to 130 minutes). The time to offset of psilocybin orally is about 6 to 7 hours on average. The duration of action of psilocybin is about 4 to 6 hours (range 3–12 hours) orally. A small dose of 1 mg by intravenous injection had a duration of 15 to 30 minutes. In another study, 2 mg psilocybin by intravenous injection given over 60 seconds had an immediate onset, reached a sustained peak after 4 minutes, and subsided completely after 45 to 60 minutes.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.